Latest California Healthline Stories
I Write About America’s Absurd Health Care System. Then I Got Caught Up in It.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: The Big Biden Budget Bill Passes the House
President Joe Biden’s social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week’s Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
How Rural Communities Are Losing Their Pharmacies
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
Cómo las comunidades rurales están perdiendo sus farmacias
Las farmacias de las esquinas, que alguna vez estuvieron tanto en las grandes ciudades como en los pueblos rurales, están desapareciendo de muchas áreas del país, dejando a unos 41 millones de estadounidenses en lo que se conoce como “desiertos de farmacias”, sin fácil acceso a las farmacias.
Despite Restraints, Democrats’ Drug Pricing Plan Could Still Aid Consumers
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiaries’ out-of-pocket drug costs at $2,000 a year.
La nueva legislación bajaría dramáticamente el precio de la insulina, y lograría que el impacto de los precios astronómicos no recaigan en el consumidor.